Brivaracetam - UCB Pharma
Alternative Names: BRIVIACT; BRIVIACT CV; BRIVLERA; RIKELTA; UCB-34714Latest Information Update: 09 Aug 2024
At a glance
- Originator UCB
- Class Antiepileptic drugs; Neuroprotectants; Non-opioid analgesics; Nootropics; Pyrrolidinones; Small molecules
- Mechanism of Action Sodium channel antagonists; SV2A protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Epilepsy
- Phase III Absence epilepsy
- Discontinued Myoclonic epilepsies; Postherpetic neuralgia
Most Recent Events
- 10 Jul 2024 Phase-III clinical trials in Absence epilepsy (In children, In adolescents, In adults, In the elderly) in USA (PO, Liquid) (NCT06315322)
- 10 Jul 2024 Phase-III clinical trials in Absence epilepsy (In children, In adolescents, In adults, In the elderly) in USA (PO, Tablet) (NCT06315322)
- 26 Jun 2024 Registered for Epilepsy (Adjunctive treatment, In adolescents, In adults, In the elderly) in South Korea (PO) before June 2024